Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy: Volume 4

ISBN-13: 9780128164358 / Angielski / Twarda / 2018 / 292 str.

Zhe-Sheng (Jason) Chen; Dong-Hua Yang

Spis treści

1. EGFR and HER2 inhibitors as sensitizing agents for cancer chemotherapy2. BCR-ABL inhibitors as sensitizing agents for cancer chemotherapy3. VEGFR inhibitors as sensitizing agents for cancer chemotherapy4. ALK inhibitors as sensitizing agents for cancer chemotherapy5. JAK2 inhibitors as sensitizing agents for cancer chemotherapy6. FLT3 inhibitors as sensitizing agents for cancer chemotherapy7. BRAF inhibitors as sensitizing agents for cancer chemotherapy8. Bruton kinase inhibitors as sensitizing agents for cancer chemotherapy

O autorze

Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press ("Cancer Sensitizing Agents for Chemotherapy,” "Breaking Cancer Resistance to Therapeutic Antibodies,” and "Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett. Zhe-Sheng Chen opened the St. John's University's first cancer pharmacology laboratory. His research interest is multidrug resistance and its reversal, novel anti-cancer drug development. Chen serves as Editor of "African Journal of Pharmacy and Pharmacology"; Editor-in-Chief of "Journal of Cancer Research Updates" and "Journal of New Developments in Chemistry". He also serves as an Editorial Board member of 25 journals, an Ad Hoc reviewer of 180 journals, and a guest editor of "Current Pharmaceutical Biotechnology", "Cancer" and "Journal of International Medical Research". Chen has over 170 papers published, 6 book chapters, and 5 patents. Dong-Hua Yang is an Assistant Professor at St. John's University College of Pharmacy and Health Sciences. She works in the fields of Cancer Biomarkers and Cancer Pharmacology. Before joining St. John's, she was a Research Assistant Professor at Fox Chase Cancer Center, where she took charge of the Tissue Research Service at the Biosample Repository Core Facility. She is a leading expert in the field of immunohistochemistry (IHC) and IHC quantitative analysis. She applied IHC technology to study the molecular alterations of known and novel signaling pathways that regulate embryogenesis, organ morphogenesis and tumorigenesis. Yang leads the automatic quantitative analysis (AQUA) for immunohistochemistry and immunofluorescence assays for biomarker research. Yang is the regional editor of "Current Proteomics”, guest editor of "Frontiers of Pharmacology”, "Cancers” and "Molecules”, associate editor of " Journal of Nutritional Therapeutics”, "Journal of Cancer Research Updates” and "Journal of Analytical Oncology”, ad hoc reviewer of 0ver 50 journals. Yang has over 70 papers and 4 book chapters published.